YDESNasdaqServices-Medical LaboratoriesFiscal year ends December 31Also trades as YDESW
YD Bio Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026
$6.12+0.20 (+3.38%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$13.97 (−69.54%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
YD Bio Ltd grew revenue 16.9% to $596.82K over fiscal 2025. Free cash flow was -$8.04M.
Revenue
$596.82K
+16.9% vs. a year earlier
Operating income
-$5.27M
FY2025
Free cash flow
-$8.04M
FY2025
EPS, diluted
-$0.12
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $596.82K
- Net income
- -$8.31M
- EPS, diluted
- -$0.12
- Free cash flow
- -$8.04M
Four years at a glance
Fiscal years 2022 to 2025, USD
Revenue
$596.82K+16.9% YoY
Gross profit
$167.41K+7.8% YoY
Operating income
-$5.27M
Net income
-$8.31M
EPS, diluted
-$0.12
Free cash flow
-$8.04M
Reported period